Gemina Laboratories Ltd. (GLABF)

0.3700 0.0000 (0.00%) At close: 10:41AM EDT

Gemina Laboratories Ltd.

3600 Gilmore Way
Unit 302
Burnaby, BC V5G 4W8
Canada

https://www.geminalabs.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 6

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Brian Firth	CEO & Director	N/A	N/A	N/A
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA	CFO & Company Secretary	N/A	N/A	1960
Dr. Robert Crandall Greene	CTO & Director	N/A	N/A	N/A
Mr. Hugh McNaught	VP of Marketing & Member of Advisory Board	N/A	N/A	N/A
Mr. David Browning FCIM, M.Sc.	Head of Productization & Director of Gemina Laboratories (UK) Limited	N/A	N/A	N/A
Dr. Christine Buerki Ph.D.	Head of Product Development	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops Legio X, a COVID-19 rapid antigen test that validating the Gemina Surface Chemistry on this platform; and LEGIO X, an influenza AB multiplex lateral flow test. It is also developing a pipeline of products for the diagnosis of infectious respiratory diseases. The company was incorporated in 2017 and is headquartered in Burnaby, Canada.

Corporate Governance

Gemina Laboratories Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.